Company Overview of Synthetic Genomics, Inc.
Synthetic Genomics, Inc., a synthetic biology company, develops and commercializes genomic-driven solutions and products for various industries worldwide. The company focuses on various commercialization programs, including developing synthetic DNA products, tools, and instruments for organizations with demands for large and/or complex DNA constructs; algae based food and nutritional products, and biofuels; and synthetically-derived vaccines and anti-microbials. It also develops clean water technologies using microbial fuel cells; and sustainable agricultural products. Synthetic Genomics, Inc. was formerly known as Synthetic Genomic Solutions, Inc. The company was founded in 2005 and is base...
11149 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2005
Key Executives for Synthetic Genomics, Inc.
Chief Executive Officer and Director
Co-Founder, Executive Chairman and Co-Chief Scientific Officer
Co-Founder, Co-Chief Scientific Officer and Director
Co-Founder, Executive Vice President, General Counsel and Director
Co-Founder, Chief Business Officer and Director
Compensation as of Fiscal Year 2014.
Synthetic Genomics, Inc. Key Developments
Synthetic Genomics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015
Feb 22 15
Synthetic Genomics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.
Synthetic Genomics, Inc. Appoints Oliver Fetzer as Chief Executive Officer and Director
Oct 27 14
Synthetic Genomics, Inc. announced the appointment of Oliver Fetzer as a Chief Executive Officer (CEO). In his role as CEO, Fetzer will also be a member of SGI's Board of Directors. Dr. Fetzer will lead all aspects of SGI, including management of SGI's three business units--SGI-DNA, Synthetic Genomics Vaccines, Inc. (SGVI), and Genovia Bio. Dr. Fetzer comes to SGI from Cerulean Pharma Inc., where he was President and CEO for five years.
Avoca, Inc. Signs Supply Agreement with Synthetic Genomics, Inc. to Become Domestic Source of Natural Astaxanthin
Jun 20 14
Avoca, Inc. has formed a supply agreement with Synthetic Genomics, Inc. to extract and commercialize natural astaxanthin from a strain of algae developed by SGI. The multi-year supply agreement also provides Avoca with exclusivity for product sales in North America. Pharmachem Laboratories will be responsible for marketing and sales. SGI is developing this product through their Genovia Bio business unit, which is responsible for the development and commercialization of algal-based food, chemical and fuel products. Financial details were not disclosed. Natural astaxanthin is a supplement with multiple clinically-proven health benefits associated with its powerful antioxidant and anti-inflammatory properties. Natural astaxanthin is very difficult to produce and therefore supply constrained relative to demand. SGI has developed a process for production of natural astaxanthin from a phototrophic source and demonstrated commercial-scale manufacturing capability and performance over 18 months. SGI's natural astaxanthin has U.S. Food and Drug Administration regulatory approval for dietary supplement applications.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|